Wyeth has reported results for second quarter ended September 30, 2012.
The company’s net profit for the quarter declined by 10.90% at Rs 30.25 crore as compared to Rs 33.95 crore for the same quarter in the previous year. Total income of the company has increased by 5.35% at Rs 157.14 crore for quarter under review as compared to Rs 149.16 crore for the quarter ended September 30, 2011.
Wyeth is the Indian subsidiary of US-based Pharma Company Wyeth, a global leader in pharmaceutical, consumer healthcare and animal health products. The pharmaceuticals business of the company comprises bulk drugs and formulations, such as oral contraceptives, hormone replacement therapy, antibiotics, vaccines, steroids and other prescription medicines. The company also manufactures OTC pharmaceuticals, cosmetics, toiletries and other allied consumer products.
